In Brazil, the team tested the antibiotic for 14 days in mice and 49 people with panic disorder, alongside clonazepam, using carbon dioxide inhalation to trigger attacks.
Both treatments lowered attack severity, while minocycline also dampened microglial activity in a brainstem region tied to CO2 detection and showed anti-inflammatory protein changes in humans.
Researchers say the already approved drug could offer a faster route to a lower-dose alternative with fewer side effects, but larger clinical trials are still needed.
With serious risks for both old and new drugs, what does a truly safe solution for panic disorder look like?
Can an antibiotic truly treat panic attacks without worsening the global antibiotic resistance crisis?
Is calming the brain's immune system, not altering its chemistry, the future of treating anxiety?
Minocycline’s Anti-Inflammatory Action Offers New Hope for 30-50% of Panic Disorder Patients Resistant to Traditional Treatments
Overview
In April 2026, researchers from UNESP and UFRJ, supported by FAPESP, published a study showing that minocycline, an approved antibiotic, effectively reduces panic attack severity by calming brain inflammation. Tested in both mice and humans under CO₂ challenge, minocycline matched the efficacy of clonazepam but worked differently by inhibiting microglial activation and lowering pro-inflammatory cytokines while increasing anti-inflammatory IL-10. This mechanism stabilizes the brain's panic center, offering a safer alternative without sedation or dependency risks. With its established safety and lower dosing, minocycline is poised for accelerated clinical trials and could transform treatment for patients resistant to current therapies, marking a paradigm shift toward neuroimmune-based mental health care.